Starpharma
(ASX:SPL) has today announced that it has received a further regulatory approval in another Asian country for its product VivaGel® BV.
This approval follows multiple country approvals in the region as previously announced on 15 August 2019.
Mundipharma will be rolling-out the product in Asia under the brand name BETADINE BV Gel.
In addition to these approvals, Starpharma and Mundipharma have submitted further regulatory submissions in countries across Asia and other Mundipharma regions.
The specific countries which have been granted regulatory approval in Asia currently remain undisclosed at this time for competitive reasons.
Shares in Starpharma
(ASX:SPL) are trading 3.04 per cent lower at $1.11.
